The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Unmet needs in the treatment of T-cell malignancies
Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses unmet needs in T-cell lymphoma, highlighting the limited treatment options available for patients and the need to improve options for patients with relapsed disease, who generally have a poor outcome. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE
